Mexico - Delayed Quote MXN

Novartis AG (NVSN.MX)

1,540.01 0.00 (0.00%)
At close: April 12 at 12:19 PM CST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in MXN.
NameTitlePayExercisedYear Born
Dr. Vasant Narasimhan M.D. Chief Executive Officer 136.44M -- 1976
Mr. Harry Kirsch Chief Financial Officer 67.92M -- 1965
Mr. Victor Bulto President of US 55.84M -- 1978
Dr. Patrick Horber M.D. President of International 124.49M -- 1970
Dr. Steffen Lang Ph.D. President of Operations 39.79M -- 1967
Paul Penepent Head of Group Financial Reporting and Accounting -- -- --
Dr. Samir Shah M.D. Global Head of Investor Relations -- -- 1962
Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer 26.46M -- 1968
Ms. Karen L. Hale Chief Legal Officer 39.91M -- 1968
Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer 35.78M -- 1968

Novartis AG

Lichtstrasse 35
Basel, 4056
Switzerland
41 61 324 1111 https://www.novartis.com
Sector: 
Healthcare
Full Time Employees: 
76,057

Description

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AG’s ISS Governance QualityScore as of April 1, 2024 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 07, 2024
    Ex-Dividend Date

Upcoming Events

Related Tickers

BAYN.MU Bayer AG
27.33
+1.15%
 
BAYN.SG Bayer AG
27.35
+1.47%
 
GRF.MC Grifols, S.A.
8.40
+0.26%
 
BIIB Biogen Inc.
201.99
+4.56%
 
MRK Merck & Co., Inc.
127.00
+0.09%
 
LLY Eli Lilly and Company
732.20
-1.81%
 
PFE Pfizer Inc.
26.27
-0.19%